Dear Editor, A first-in-class microbiota-based live biotherapeutic, originally termed RBX2660, was approved by the U.S. Food and Drug Administration (FDA), on November 30, 2022 [1]. RBX2660 works by preventing recurring Clostridioides difficile infections (CDI) in adults aged 18 or above; these infections typically follow antibiotic treatment. Patients with CDI have limited therapeutic options and undergo debilitating symptoms preventing them from leaving homes and leading to isolation. RBX2660, as a newly approved biotherapeutic, is expected to impact the entire healthcare delivery system.
